Robert J. Hariri
Robert J. Hariri's purchase track record
Robert J. Hariri has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/29/2023 | CELU | $2.98M | +11.3% | +138.3% | +22.3% |
| 11/28/2022 | CELU | $155K | -59.1% | -55.5% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioVie Featured on Bloomberg Television Segment. BioVie was included in a new episode of The Street Show airing on Bloomberg Television. The segment also featured Glint, Sagtec Global, and SafeSpace Global. This media appearance provides additional visibility for the company to a financial audience.
Transaction History
| CYRX | ▲ Buy | Grant | 10,350 | $0 | 6/5/2026 | View on chart |
| CELU | ▲ Buy | Option Exercise | 3,281 | $0 | 4/13/2026 | View on chart |
| CELU | ▼ Sell | Tax Withholding | 1,182 | $2K | 4/13/2026 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 50,000 | $133K | 9/11/2025 | View on chart |
| CYRX | ▼ Sell | Open Market | 25,000 | $243K | 9/11/2025 | View on chart |
| CYRX | ▼ Sell | Open Market | 5,000 | $43K | 8/22/2025 | View on chart |
| CYRX | ▲ Buy | Grant | 23,214 | $0 | 6/6/2025 | View on chart |
| CYRX | ▼ Sell | Open Market | 12,500 | $76K | 5/28/2025 | View on chart |
| CELU | ▲ Buy | Option Exercise | 3,281 | $0 | 4/13/2025 | View on chart |
| CELU | ▼ Sell | Tax Withholding | 1,154 | $2K | 4/13/2025 | View on chart |
| CYRX | ▼ Sell | Open Market | 2,500 | $16K | 11/21/2024 | View on chart |
| CYRX | ▼ Sell | Open Market | 1,000 | $9K | 8/19/2024 | View on chart |
| CYRX | ▼ Sell | Open Market | 1,000 | $9K | 8/16/2024 | View on chart |
| CYRX | ▼ Sell | Open Market | 1,000 | $8K | 8/14/2024 | View on chart |
| CYRX | ▲ Buy | Grant | 12,845 | $0 | 5/17/2024 | View on chart |
| CELU | ▼ Sell | Tax Withholding | 1,154 | $5K | 4/13/2024 | View on chart |
| CYRX | ▼ Sell | Open Market | 800 | $14K | 12/14/2023 | View on chart |
| CYRX | ▼ Sell | Open Market | 1,000 | $16K | 12/11/2023 | View on chart |
| BIVI | ▲ Buy | Grant | 42,254 | $0 | 11/9/2023 | View on chart |
| CELU | ▲ Buy | Open Market | 3,050,427 | $484K | 10/5/2023 | View on chart |
| CELU | ▲ Buy | Open Market | 6,307,158 | $1.0M | 10/5/2023 | View on chart |
| CELU | ▲ Buy | Open Market | 9,064,539 | $1.5M | 9/29/2023 | View on chart |
| CYRX | ▼ Sell | Open Market | 1,500 | $20K | 9/6/2023 | View on chart |
| CYRX | ▲ Buy | Grant | 8,105 | $0 | 5/12/2023 | View on chart |
| CELU | ▼ Sell | Tax Withholding | 11,540 | $8K | 4/13/2023 | View on chart |
| CELU | ▲ Buy | Grant | 2,084,854 | $1.7M | 3/27/2023 | View on chart |
| CELU | ▲ Buy | Open Market | 10,000 | $17K | 11/30/2022 | View on chart |
| CELU | ▲ Buy | Open Market | 40,000 | $68K | 11/29/2022 | View on chart |
| CELU | ▲ Buy | Open Market | 40,000 | $70K | 11/28/2022 | View on chart |
| BIVI | ▲ Buy | Grant | 34,240 | $0 | 11/23/2022 | View on chart |
| CELU | ▲ Buy | Option Exercise | 119,073 | $342K | 8/24/2022 | View on chart |
| CYRX | ▼ Sell | Open Market | 2,000 | $87K | 8/11/2022 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 2,708 | — | 4/30/2022 | View on chart |
| CYRX | ▲ Buy | Grant | 7,203 | $0 | 4/29/2022 | View on chart |
| CELU | ▲ Buy | Grant | 131,234 | — | 4/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline
BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline. BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.